-- Earnings Flash (ABIO) ARCA BIOPHARMA Posts Q2 Loss $-0.22
4:19PM ET 8/02/2022 MT Newswires...
Quotes Snapshot > ABIO
ARCA Biopharma Inc ABIO:NASDAQ
Last Price$2.47NASDAQ Previous Close - Last Trade as of 3:59PM ET 8/12/22
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$2.30 (23)
Ask (Size)$2.47 (13)
Day Low / HighN/A - N/A
Volume30.2 K
Read more news Recent News
Arca Biopharma Board to Weigh Strategic Options for Company -- Shares Rise After-Hours
4:57PM ET 4/18/2022 MT NewswiresArca Biopharma (ABIO) said Monday its board formed a special committee of directors to study potential strategic options to maximize stockholder value. ...
Correction: Sector Update: Health Care Stocks Finishing Near Friday Session Highs
10:51AM ET 4/04/2022 MT Newswires(Corrects to show correct name of Sage's drug candidate in third paragraph.) Health care stocks added to their midday gains this afternoon, with the NYSE...
View all Commentary and Analysis
ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play
11:50AM ET 5/03/2022 Seeking AlphaIPO Update: Nuvo Group Seeks $10 Million IPO
4:00PM ET 12/13/2021 Seeking AlphaNuvo Group Begins U.S. IPO Effort
2:06PM ET 11/30/2021 Seeking AlphaU.S. IPO Weekly Recap: The Shortened Holiday Week Brings Just 1 IPO
10:43PM ET 11/27/2021 Seeking AlphaCompany Profile
Business DescriptionARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on the cardiovascular pathophysiology, molecular genetics, and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO. View company web site for more details
| Address | 10170 Church Ranch Way Westminster, Colorado 80021 |
| Phone | +1.720.940.2200 |
| Number of Employees | 15 |
| Recent SEC Filing | 08/02/2022 10-Q |
| President, Chief Executive Officer & Director | Michael R. Bristow |
| Chief Operating Officer | Thomas A. Keuer |
| Chief Financial Officer | C. Jeffrey Dekker |
| Chief Medical Officer | Debra Marshall |
Company Highlights
| Price Open | $2.40 |
| Previous Close | $2.40 |
| 52 Week Range | $1.71 - 3.17 |
| Market Capitalization | $35.6 M |
| Shares Outstanding | 14.4 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/01/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.13 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -33.52% |
Analyst Ratings as of 11/11/2019
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |